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 Renal Radionuclide Studies 
 Keith  Britton 
 Our adventure with the kidneys started at the then Middlesex Hospital culminating 
in 1971 with Britton and Brown’s monograph Clinical Renography [ 1 ]. This was 
prefaced: ‘The disciplines of Medicine and Physics are like oil and vinegar – often 
shaken together, often appetising but not easily miscible’. We attempted to ‘blend 
the soothing oil of medicine with the acid reality of Physics in a study of common 
interest: how the kidney works’. We debunked the old nomenclature of the reno-
gram – the Vascular spike, the Secretory phase and the Excretory phase – for exam-
ple the latter is the ‘left behind in the kidney’ phase. We proposed ‘Second phase’ 
for the rising portion and ‘Third phase’ for the descending portion of the renal activ-
ity time curve. We cleaned up the renogram with Computer assisted blood back-
ground subtracted, CABBS, Renography [ 2 ]. With a grant from the Leverhulme 
Trust, we developed a mobile Renography trolley and couch with Nuclear 
Enterprises of Edinburgh, which could be taken to the Intensive care unit and the 
patient transferred onto it. 
 NJG, Nick, Brown fi rst showed the importance of the integral of the Blood clear-
ance curve [ 1 ,  3 ], later used as the Patlak or Rutland plot (Mike Rutland did his MSc 
with us). It led to the numerical approach to measuring the Outfl ow Effi ciency. Nick 
also developed various renal transit times. 
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10.1  Essential Hypertension 
 Using the bimodal distribution of transit times, we were able to separate the contri-
butions of the Cortical and Juxta-medullary nephrons to renal blood fl ow [ 4 ]. These 
were validated in animal studies with Steve Wilkinson at King’s College. We were 
able to show that in Essential Hypertension, Cortical blood fl ow is reduced and 
Medullary blood fl ow is increased [ 5 ], the former increasing salt retention and the 
latter accounting for loss of urine concentrating ability, Nocturia being a common 
symptom of early Hypertension. We were also able to show that Captopril greatly 
improved Cortical nephron fl ow and reduced blood pressure. It led to Lancet publi-
cations of the hypothesis ‘Renin and Renal Autoregulation’ [ 6 ] and ‘Essential 
Hypertension: a disorder of cortical nephron control’ [ 7 ]. 
10.2  Measurement Based Medicine 
 These approaches were based on the premise that numerical indices of renal radio-
nuclide studies were better than eye-balling and guessing the meaning of a complex 
activity time curve. Indeed our philosophy became a wish to substitute ‘Evidence 
based medicine’ which applied to the many with ‘Measurement based medicine’ 
which applied to the individual through ‘Normal ranges’ and ‘Action determining 
ranges’. For example in adults one should act to save a kidney with more than 15 % 
of total renal function, but not if it is less that 5 % of total. Sreenevasan’s dictum was 
made during my IAEA time in Malaysia ‘In the presence of bilateral outfl ow 
obstruction (usually uric acid stones) always operate on the kidney with the better 
relative function fi rst as determined by renography’ [ 8 ]. 
 The refi nements occurred at St Bartholomew’s Hospital in the City of London 
through the Physicist Cyril Nimmon’s expertise and dedication. The Gamma cam-
era replaced the probes and his advanced computer programmes enhanced and sim-
plifi ed the results [ 9 ]. 
10.3  Outflow Efficiency 
 The Outfl ow effi ciency [ 10 ] is determined by subtracting the renal activity time 
curve from the integral of the blood clearance curve (the input curve) fi tted to its 
second phase to give the integral of the output curve. This output curve is then taken 
as a percentage of the input curve. Unlike Frusemide dependent measurements, it is 
independent of the level of renal function. Normally a kidney should excrete over 
78 % of what it took up within 30 min. 
10.4  Transit Times 
 Renal Transit times seem to confuse some practitioners. Think of ‘Pooh sticks’. On 
one side of the bridge a bunch of sticks are thrown into the stream together. You run 
to the other side of the bridge and see one stick coming out fi rst followed by a 
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distribution of others. The distribution of times they take to pass under the bridge 
can be measured and a mean time of transit determined. The mathematical process 
is Deconvolution. The result tends to be noisy. Three factors made it usable. Firstly 
the high count rate given by Tc-99m MAG3. This was fi rst used in the UK in our 
department and published by Dr now Professor Adil Al Nahhas [ 11 ]. Secondly 
Cyril Nimmon devised two constraints on the activity time curve, monotonicity and 
non- negativity; and a lack of over-smoothing of the original data; thirdly the use of 
the left ventricle to give the blood clearance curve as a high count input. 
 The understanding of Transit times by the clinician may be likened to learning to 
ride a bicycle. One falls off several times at the start and either gives up as many 
have; or persists until one avoids the potholes and is rewarded by the ride. 
10.5  Renovascular Disorders 
 It may be noted that renal radionuclide studies do not generally distinguish between 
large and small vessel renal disease if they are functionally signifi cant in contribut-
ing to hypertension. The Mean Parenchymal Transit Time, MPTT is normally less 
than 240 s. In the context of Hypertension due to Renovascular disorder such as 
Renal artery stenosis, it exceeds this and indicates the narrowing is functionally 
signifi cant. It is further increased in this context by Captopril, particularly in large 
vessel disease. Gruenewald et al. [ 12 ], who did his MSc with us, showed that if 
MPTT was prolonged then most hypertensive patients are benefi tted by revasculari-
sation or stenting with a reduction of their Blood Pressure, but if MPTT was normal 
in this context, none of the Hypertensive patients benefi tted. 
10.6  Obstructing Uropathy 
 Consider some basics, there is the Force from cardiac output, which does not change 
if there is a stone blocking urine fl ow. There is the Resistance to urine fl ow. The con-
sequence of the interaction of a Force and a Resistance is a rise in Pressure. Pressure 
is not a cause but a consequence. Pressure is equal and opposite in all directions (Sir 
Isaac Newton) so there is no such thing as ‘back pressure’. When there is a system of 
fl uid in a tube, it fl ows from the higher pressure to the lower pressure. A non reabsorb-
able agent such as Tc-99m MAG3 therefore takes time to travel down this pressure 
gradient. In Obstructing Uropathy, the resistance to fl ow increased so the solute takes 
longer to transit. Increased resistance to fl ow is thus transmutable into an increased 
transit time which can be measured. In this context the Parenchymal Transit Time 
Index, PTTI is helpful. It is measured as the MPTT minus the Minimum (shortest) 
Transit time which makes an allowance for different urine fl ow rates. Normal PTTI is 
less than 156 s. Unlike Frusemide based studies, it is independent on the level of renal 
function, although there has to be suffi cient function for the measurement to be made. 
The Urologist Mr Hugh Whitfi eld at St Barts gained the Hunterian award for evaluat-
ing the advantages of using PTTI in the context of potential Obstructing Uropathy [ 13 , 
 14 ]. An abnormal PTTI is one of the earliest indicators of functionally signifi cant 
Obstructing Uropathy in adults, for example when renal function is still normal. It is 
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also independent of the size of the renal pelvis. If the words ‘outfl ow obstruction’ or 
worse ‘partial obstruction’ were replaced by ‘increased resistance to fl ow’, the under-
standing of an ‘outfl ow obstruction’ would be made easier. 
 The above is a simplifi cation of Transit time usage, which needs some interpre-
tive skill, for example PTTI may be unreliable if MPTT is abnormal. Transit time 
indices should be taken together with other clinical information and renal measure-
ments in a holistic approach. 
10.7  Frusemide Response 
 There are a number of ways of evaluating the response to Frusemide. Visually one 
may compare the rising second phase with the falling third phase of the activity 
time curve. If the rate of fall of the third phase before or after Frusemide is appro-
priate to the rate of rise of the second phase, then no Obstructive Nephopathy is 
likely. However using a T1/2 or other measure of the rate of fall of the third phase 
will be normal if renal function is good and abnormal if renal function is poor. It 
is not to be relied upon. Our usual protocol is to inject Frusemide at 16 min 
(F + 16) so that one can see the visual effect of Frusemide on any pelvic retention 
of tracer and its effect on the third phase of the activity time curve. When 
Frusemide is given 15 min before the start of the renal activity time curve, (F-15), 
which was previously used when the renogram was equivocal, the response to 
Frusemide cannot be assessed, except by comparison with a previous study with-
out F-15. F-15 often causes the patient urinary urgency and may cause early ter-
mination of the study. 
 The numerical indices Outfl ow effi ciency [ 15 ] and Parenchymal transit time 
index [ 16 ] avoid the need for F-15 in equivocal studies. 
 Whereas MAG3 is anionically bound, Cyclosporine is cationically bound in 
the kidney, hence the lack of reliability of Tc-99mMAG3 in this context of 
renal transplantation. Ajit Padhy and Kishor Solanki developed a new cationic 
binding agent Tc-99m DACH intended for the evaluation of cyclosporine tox-
icity [ 17 ]. Jamshed Bomanji among many other contributions showed the early 
beneficial effects of Lithotripsy on the outcome of the treatment of renal cal-
culi [ 18 ]. We developed a ‘bootstrap’ model of the ‘Counter Current’ mecha-
nism of urinary concentration with our systems analysis colleagues from City 
University [ 19 ]. In conclusion we emphasised that Nuclear Medicine allowed 
the appreciation and measurement of renal physiology and patho-physiological 
processes in man. 
 Since this section was to be related mainly to the work at St Bartholomew’s 
Hospital, I apologize for being unable to mention the works of many others in renal 
function measurements, renal transplants, renal tumours and Paediatrics. With their 
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 Keith  Britton  I was educated at Malvern College, Downing College, Cambridge and the then 
Middlesex Hospital, London. I was registrar to Dr John Nabarro and Dr ‘Willy’ Slater and carried 
out the hospital’s fi rst renal dialysis. I became fascinated with Nuclear Medicine as a non-invasive 
tool to study how organs functioned in people and not just their anatomy. I studied with Prof 
Edward Williams at the Institute of Nuclear Medicine, Middlesex Hospital gaining the MSc; and 
an MD at Cambridge examined by Professor Norman Veall. He said that he had repeated my work 
on renal transit times and agreed with it. That was the exam! I became registrar to Professor 
Stanley Peart at St Mary’s Hospital, learning about the management of Hypertension. This pre-
pared me for my part in the Hypertension Clinic at St Bartholomew’s Hospital. I was appointed as 
a General Physician at St Barts. If the clinic staff could not decide on the specialty to which a GP 
had referred a patient, then it would go to me as a generalist to sort out in the outpatient clinic. 
 I then became a Professor of Nuclear Medicine at the Medical school and Queen Mary College, 
giving up my ward duties at St Barts. I was made director of the Nuclear Medicine group of Cancer 
Research UK, which funded staff and equipment to carry out research into imaging and therapy 
with radio-labelled monoclonal antibodies in cancers. During my time and work with the 
International Atomic Energy Agency, we were able to welcome over 100 overseas postgraduate 
doctors to sit the MSc in Nuclear Medicine, most passed. As a past President of the Society of 
Nuclear Medicine, Europe, I was able to help to found the European Association of Nuclear 
Medicine, EANM and lead the congress in 1985 at the Barbican centre in London. 
 I was a past President of the BNMS and organised that Physicists became full members. I was 
one of the founder editors of Nuclear Medicine Communications and of the World Journal of 
Nuclear Medicine. I published over 250 peer reviewed manuscripts and several books including 
Clinical Nuclear Medicine, lead Editor Professor Michael Maisey, going on for four editions. 
 After my retirement due to age 65, I was awarded Emeritus Professor, University of London. 
I became Chair of the Board of the independent Cromwell Hospital for two and a half years. It was 
revealing to be able to manage instead of being managed by the NHS. I continue in private practice 
as Consultant in Nuclear Medicine to The London Clinic and the London Bridge Hospital. 
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